Stay updated with breaking news from World Dynamix. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Nephrologists have long considered chronic kidney disease (CKD) progression and diabetic kidney disease (DKD) as areas in dire need of new and...
Share this article Share this article EXTON, Pa., March 4, 2021 /PRNewswire/ -- Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis. At the American Society of Nephrology (ASN) fall 2020 conference, Kidney Week Reimagined, news about SGLT2 inhibitors for CKD patients with and without diabetes created a stir and caused optimism about potential paradigm shifts for CKD patients. The fierce competition between AstraZeneca and Vifor/Relypsa in the hyperkalemia...
Share this article Share this article EXTON, Pa., Feb. 11, 2021 /PRNewswire/ -- With the recent additions of Novartis' Mayzent, Bristol Myers Squibb's Zeposia, and Biogen's Vumerity to the multiple sclerosis (MS) market in the United States, neurologists increasingly choose to initiate treatment by prescribing an oral disease-modifying therapy (DMT). Data from 1,018 charts of MS patients initiated on their first DMT within the prior three months, provided by 205 neurologists as part of Spherix's RealWorld Dynamix™: DMT New Starts in Multiple Sclerosis (US) service, indicate that the oral D...
Share this article Share this article EXTON, Pa., Feb. 10, 2021 /PRNewswire/ -- Despite the potential for setbacks brought forth by the COVID-19 pandemic, Amgen recently reported strong year-over-year growth for their newly acquired psoriasis (PSO) and psoriatic arthritis (PsA) agent, Otezla. 1 In late 2019, the brand was sold to Amgen in order to clear the path for Bristol-Myers Squibb's acquisition of Celgene, considering future regulatory conflicts with BMS' pipeline psoriasis drug, deucravacitinib, an oral TYK2 inhibitor anticipated to be in direct competition with Otezla. Amgen's purch...